当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
Flucelvax Quadrivalent, Influenza Vaccine
药品名称
Flucelvax Quadrivalent, Influenza Vaccine
承诺描述
Deferred pediatric study (Study V130_10) under PREA to evaluate the safety and immunogenicity of your quadrivalent formulation of Influenza Vaccine in pediatric subjects 6 months to less than 4 years of age.
承诺状态描述
The final report was submitted to FDA on 14 Dec 2020.